peptide agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-02 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
==== Breakdown of blood-nerve barrier ==== Intraneural blood vessels, similar to other microvessels in the human body, increase their permeability in response to stress. During extended periods of metabolic stress, such as ischema caused by compression, the blood-nerve-barrier will increase in permeability. This increase in the permeability in the blood-nerve-barrier is the first pathological symptom observed during compression studies.
It was first advertised on television with the jingle "Brylcreem — A Little Dab'll Do Ya! Brylcreem — You'll look so debonair. Brylcreem — The gals'll all pursue ya; they'll love to run their fingers through your hair!". Another version was "Brylcreem—a little dab will do ya! Use more only if you dare; but watch out! The gals will all pursue ya! They'll love to run their fingers through your hair!" The jingle was created by Hanley M. Norins of the Young & Rubicam advertising agency. The television advertisement for Brylcreem included a cartoon animation of a man with (initially) shaggy hair, who happily has a little dab applied, and, miraculously, the hair combs and smooths itself. When the dry look became popular, partly inspired by the unoiled moptops of the Beatles, the last line was changed from "They'll love to run their fingers through your hair", to "They'll love the natural look it gives your hair". Subsequent television advertisements used the mottoes "Grooms without gumming" and later, in the 1970s, in the United Kingdom and Canada, "A little dab of Brylcreem on your hair gives you the Brylcreem bounce".
Also, during the 1981 tour, veteran session drummer Andy Newmark stepped in briefly for Knudsen, who was then in rehab. And by the end of 1981, even Simmons had left the band. Now with no remaining original members and a "leader" in McDonald who was ready for a solo career, the group elected instead to disband after a rehearsal without Simmons, according to an interview with McDonald for Listen to the Music, the Doobie Brothers' official video history/documentary released in 1989. He went on to say that by that point they could not have gotten further away from the Doobies sound if they had tried. Simmons, already at work on his first solo album, Arcade, rejoined for a 1982 farewell tour on the condition that this truly would be the end of the Doobie Brothers. At their last concert at the Greek Theatre in Berkeley, California, on September 11, 1982, they were joined onstage by founding member Tom Johnston for what was presumed to be the final rendition of his staple, "China Grove". Former members Porter, Hossack and Hartman subsequently took the stage for an extended version of "Listen to the Music". Knudsen sang lead vocals while Johnston, Simmons and McFee traded licks on guitar. The live album Farewell Tour was released in 1983 and the Greek Theatre concert was released in 2011 as Live at the Greek Theatre 1982.
dopaquinone → leucodopachrome → dopachrome → 5,6-dihydroxyindole-2-carboxylic acid → quinone → eumelanin dopaquinone → leucodopachrome → dopachrome → 5,6-dihydroxyindole → quinone → eumelanin Detailed metabolic pathways can be found in the KEGG database (see External links).
Sources: en.wikipedia.org
== Publications == Separation of amino acid homopolymers by capillary gel electrophoresis. Retention indices for programmed-temperature capillary-column gas chromatography of polycyclic aromatic hydrocarbons. Ultrasensitive Pheromone Detection by mammalian vomeronasal neurons. Electrophoretic separations of proteins in capillaries with hydrolytically-stable surface structures. Comparison of the methods for profiling glycoprotein glycans—HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Structural Investigations of Glycoconjugates at High Sensitivity.
Electronic cigarette aerosol contains fine and ultrafine particles of particulate matter, including particulate matter 2.5 μm or smaller in diameter (PM2.5). Studies have found that electronic cigarette aerosol can raise PM2.5 concentrations to several hundred micrograms per cubic meter (μg/m³), with measurements of 600–800 μg/m³ in vape shops and conventions and peak values exceeding 1,000 μg/m³; these levels are far above typical indoor backgrounds (8–52 μg/m³) and greatly exceed the World Health Organization’s 24‑hour PM2.5 guideline of 25 μg/m³ for outdoor air. PM2.5 is capable of penetrating deep into the lungs and entering the bloodstream, where it is associated with severe systemic inflammation, cardiovascular disease, and premature death.
direct repeat Any two or more repetitions of a specific sequence of nucleotides occurring in the same orientation (i.e. in precisely the same order and not inverted) and on the same strand, either separated by intervening nucleotides or not. An example is the sequence TACCGnnnnnnTACCG, in which TACCG occurs twice, though separated by six nucleotides that are not part of the repeated sequence. A direct repeat in which the repeats are immediately adjacent to each other is known as a tandem repeat.
This must be especially the case for LCRs found in highly expressed proteins, since they should also have a great impact on the energy burden of protein translation. Thus, any prokaryotic LCRs that constitute evolutionary accidents with no functional significance should not be fixed by genetic drift and consequently should not demonstrate any levels of conservation among moderately distant evolutionary relatives. On the contrary, any LCR found among homologs of several moderately distant prokaryotic species should very probably reserve a functional role.
In fluid dynamics, the Hagen–Poiseuille equation, also known as the Hagen–Poiseuille law, Poiseuille law or Poiseuille equation, is a physical law that gives the pressure drop in an incompressible and Newtonian fluid in laminar flow flowing through a long cylindrical pipe of constant cross section. It can be successfully applied to air flow in the airways of the lungs, or the flow through a drinking straw or through a hypodermic needle. It was experimentally derived independently by Jean Léonard Marie Poiseuille in 1838 and Gotthilf Heinrich Ludwig Hagen, and published by Hagen in 1839 and then by Poiseuille in 1840–41 and 1846. The theoretical justification of the Poiseuille law was given by George Stokes in 1845. The assumptions of the equation are that the fluid is incompressible and Newtonian; the flow is laminar through a pipe of constant circular cross-section that is substantially longer than its diameter; and there is no acceleration of fluid in the pipe. For velocities and pipe diameters above a threshold, actual fluid flow is not laminar but turbulent, leading to larger pressure drops than calculated by the Hagen–Poiseuille equation. Poiseuille's equation describes the pressure drop due to the viscosity of the fluid; other types of pressure drops may still occur in a fluid (see a demonstration here).
Sources: en.wikipedia.org
Absence of antibodies in patients with diagnoses of an autoimmune thyroid in their past would always be suspicious for development to SAT even in the presence of a normal TSH because there is no known recovery from autoimmunity. For clinical interpretation of laboratory results it is important to acknowledge that TSH is released in a pulsatile manner resulting in both circadian and ultradian rhythms of its serum concentrations.
== Knockout and functional evidence == The signaling molecule Wnt7-a is expressed within the female embryo, controlling the proper establishment of the uterus and the anterior-posterior axis within the female reproductive tract. Prenatal knockout of the Wnt7-a gene disrupts the early stages of the female reproductive tract, resulting in the lack of a comprehensive analysis of the gene’s role in development. However, a conditional knockout of the gene after birth, provided greater insight into the role of the gene in terms of uterine development. Initial appearance between the control mice and mutant mice appear similar, as both models presented with a vagina, cervix, oviduct, and ovary. In postnatal development, the Wnt7-a-null mice failed to develop endometrial glands and lacked the expression of genes Foxa2, Hoxa10, Hoxa11, Msx1, and Wnt16. The lack of endometrial glands within the mice resulted in infertility, as blastocyst failed to implant in the immature uterus. Loss of Wnt7-a during prenatal development results in absence of normal female anatomy and infertility while loss of Wnt7-a during postnatal development results in the presence of normal female anatomy and infertility.
The foundation charged the new project with development, testing, licensure and mass introduction of a meningococcal conjugate vaccine. In 2002, the collaboration supported reinforced meningitis surveillance activities in 12 countries in Africa: Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Ethiopia, Ghana, Ivory Coast, Mali, Niger, Nigeria and Togo. The surveillance indicated an increased risk of outbreaks in the future and the continued need for a vaccine. MenAfriVac became available for widespread use in African meningitis belt countries in 2010. Distribution in Mali and Niger was assisted by Médecins Sans Frontières.
== X == Xiuhpōhualli – A 365-day solar calendar used by the Aztecs and other pre-Columbian Nahua peoples in central Mexico. It consisted of eighteen 20-day periods plus a five-day period known as Nemontemi, considered to be unlucky. Used to track agricultural cycles and schedule religious festivals, it functioned alongside the 260-day Tonalpohualli ritual calendar; together these formed a 52-year calendar round.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.